ProShares Ultra Nasdaq Biotechnology (BIB)
55.10
+0.79
(+1.45%)
USD |
NASDAQ |
Nov 21, 16:00
55.26
+0.16
(+0.29%)
After-Hours: 20:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| -- | Upgrade | -- | Upgrade |
Basic Info
| Investment Strategy | |
| General | |
| Security Type | |
| Equity Style | |
| Fixed Income Style | |
| Broad Asset Class | |
| Broad Category | |
| Category Name | |
| Category Index | |
| Global Category Name | |
| YCharts Categorization | Alts |
| YCharts Benchmark | Private Equity Index Total Return (^PEATR) |
| Prospectus Objective | |
| Fund Owner Firm Name | |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology TR USD | 200.0% |
| Broad Asset Class Benchmark Index | |
| 100.0% | |
| Manager Tenure | |
| Michael Neches | 11.09 yrs |
| Tarak Davé | 6.51 yrs |
Performance Versus Category
Annual Total Returns Versus Peers
As of November 22, 2024.
Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | -- | -- | -- |
| Stock | -- | -- | -- |
| Bond | -- | -- | -- |
| Convertible | -- | -- | -- |
| Preferred | -- | -- | -- |
| Other | -- | -- | -- |
Basic Info
| Investment Strategy | |
| General | |
| Security Type | |
| Equity Style | |
| Fixed Income Style | |
| Broad Asset Class | |
| Broad Category | |
| Category Name | |
| Category Index | |
| Global Category Name | |
| YCharts Categorization | Alts |
| YCharts Benchmark | Private Equity Index Total Return (^PEATR) |
| Prospectus Objective | |
| Fund Owner Firm Name | |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology TR USD | 200.0% |
| Broad Asset Class Benchmark Index | |
| 100.0% | |
| Manager Tenure | |
| Michael Neches | 11.09 yrs |
| Tarak Davé | 6.51 yrs |